anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A novel action mechanism wherein androgen receptor (AR) is activated by the interaction between cyclin E and the androgen receptor was revealed. This activation is resistant to existing anti-androgen agents and both androgen receptor ligand-dependent and independent activations were found to participate in this mechanism. Methods of screening for anti-androgen agents using cyclin E are also provided by the present invention. Based on the findings as described above, novel anti-androgen agents can be screened. These anti-androgen agents are expected to be efficacious also against pathological conditions that have become resistant to existing anti-androgen agents. Thus, the instant invention opens up new possibilities for treatment using anti-androgen agents that had their limitations until now.
PURPOSE:The titled inhibitor as a good component, comprising laver in a powdered as a main ingredient. CONSTITUTION:An inhibitor against digestion and absorption of glucide, containing laver in a powdery state (dried laver, roasted laver, or raw laver before formation of laver sheet), especially powdered laver made into preferably <=2mm size as a main ingredient. The laver is directly added to a food containing glucide, or it is made into a dosage form such as tablet, pill, granule, powder, capsule, etc., and is added when a food is used. Sugar, various starches, sorbitol, mannitol, xylose, etc. be cited as glucide, and various grain foods, their processed foods, sugar-containing foods, etc., may be cited as the food containing glucide. The use of the laver in a powdery state is based on the information that a cell wall consisting of slightly digestible polysaccharide such as xylan, mannan, etc. is destroyed, and exposed substances in the cell has an inhibitory action on digestion and absorption of glucide in the body.
Glycosylphosphatidylinositol- (GPI-) anchored HSPG glypican-1 is strongly expressed in human breast and pancreatic cancer - both by the cancer cells and in the case of pancreatic cancer the adjacent fibroblasts - whereas expression of glypican-1 is low in the normal pancreas and in chronic pancreatitis.  Treatment of two pancreatic cancer cell lines, which express glypican-1, with the enzyme phosphoinositide-specific phospholipase-C (PI-PLC) abrogated their mitogenic responses to two heparin-binding growth factors: fibroblast growth factor-2 (FGF2) and heparin-binding EGF-like growth factor (HB-EGF). Treatment of MDA-MB-231 and MDA-MB-468 breast cancer cells with PI-PLC abrogates the mitogenic response to two heparin-binding growth factors, heparin-binding epidermal growth factor-like growth factor (HB-EGF) and fibroblast growth factor-2 (FGF-2). Syndecan-1 is also expressed at high levels in breast cancer tissues as well as breast cancer cells by comparison with breast normal tissues. Temporary or permanent transfection of a glypican-1 antisense construct attenuated glypican-1 protein levels and the mitogenic response to FGF2 and HB-EFG. Glypican can be used to detect the carcinoma in vitro and therapeutics that either bind to (e.g., antibodies or drugs), remove (e.g., enzymes) or prevent the expression (e.g., antisense constructs) of surface of the extracellular domain of glypican-1 are effective in retarding the growth of glypican-responsive carcinomas.
The investigators have developed and assessed the feasibility of performing whole---body multi---parametric MRI for staging metastatic disease. The investigators hypothesize that a whole body multi---parametric MRI will be more sensitive and specific than conventional imaging staging for detection of metastatic disease in patients with biochemical failure following local therapies. Investigators therefore propose a comparative trial of conventional imaging verses whole---body multi---parametric MRI within this population of men. The investigators would further like to explore whether heterogeneity between metastases of multi---parametric MRI signals can predict men unlikely to respond to ADT. The investigators aim to enhance the main study by exploratory work on exosome, pathway and genomic analysis, the results of which could lead to complimentary imaging / non---imaging biomarker combinations of clinical utility for patient stratification. Finally the investigators will perform a health economic analysis to assess the cost---effectiveness of whole---body multi---parametric MRI for metastatic disease staging compared with conventional staging with computed tomography and bone---scans.
An analytics system uses one or more machine-learned models to predict a hormone receptor status from a H&E stain image. The system partitions H&E stain images each into a plurality of non-overlapping image tiles. Bags of tiles are created through sampling of the image tiles. For each H&E stain image, the system generates a feature vector from a bag of tiles sampled from the partitioned image tiles. The analytics system trains one or more machine-learned models with training H&E stain images having a positive or negative receptor status. With the trained models, the analytics system predicts a hormone receptor status by applying a prediction model to the feature vector for a test H&E stain image.
Drainage of the space between the ribs and lungs has been practiced since the time of Hippocrates. Thus far, the function of chest tubes, specifically to drain fluid or air from the pleural space, has virtually remained unchanged for more than 3000 years. The use of chest drainage tubes after thoracic surgery is crucial to evacuate air leakage and/or pleural effusion; however, delayed tube removal may exacerbate pain, delay recovery of lung function and prolong hospitalization. Recently, Thopaz digitally monitored thoracic drainage system (Medela Healthcare, Baar, Switzerland)has been designed to provide objective measurements of air leakage and pleural pressure. With this system, air leakage and pleural pressure can be accurately measured in mL/min and mm H2O, respectively. The rate of air leakage can be seen on a display in real time. Digital surveillance for air leakage is reported to reduce interobserver disagreement in decision making in the management of patients with chest tubes, which might help caregiver a more solid evidence of strategies of postoperative chest drainage care.
<P>PROBLEM TO BE SOLVED: To provide a hyaluronidase gene expression inhibitor and a ceramidase gene expression inhibitor, each comprising a new peptide as an effective ingredient, and a skin-beautifying composition comprising the same.  <P>SOLUTION: The features of this invention are as follows. (1) The hyaluronidase gene expression inhibitor comprises a peptide derived from rice as an effective ingredient. (2) The ceramidase gene expression inhibitor comprises a peptide derived from rice as an effective ingredient. (3) The skin-beautifying composition comprises a peptide derived from rice as an effective ingredient.  <P>COPYRIGHT: (C)2011,JPO&INPIT
Ultrasound to measure fetal growth every 2 weeks (i.e. 28, 30, 32, 34, 36, 38 weeks gestation).
In Dosing Session 5, the subjects will be administered GSK356278 50 mg and placebo in a fasted state. The subjects will undergo food assessment session in Session 5 incase they experience nausea. In food assessment session, the subjects will receive a dose of GSK356278 after a standard breakfast.
NEW MATERIAL:A derivative expressed by the formula. EXAMPLE:A 6-thioacetylmorphine derivative. USE:Useful as an analgesic agent having powerful analgesic action and extremely low drug dependence. PREPARATION:For example, diisopropyl azodicarboxylate is dripped into a solution of triphenylphosphine in anhydrous tetrahydrofuran at 0 deg.C in an argon steam and the resultant solution is stirred. Thioacetic acid and a solution of morphine in anhydrous tetrahydrofuran are added to the solution while being cooled with ice and the anhydrous tetrahydrofuran is subsequently distilled away. The obtained residue is then subjected to silica gel column chromatography to afford the aimed derivative.
PROBLEM TO BE SOLVED: To provide a process which is an improved process for producing a fiber reinforced composite having a high fiber content from a fiber material formed by preimpregnating a textile part or org. matrix and does not require a high pressure for forming the fiber reinforced material. SOLUTION: The process for producing the fiber reinforced composite consists in first manufacturing a casting mold and packing the fiber reinforced, polymerizable material contg. the org. matrix and the fiber components embedded in the org. matrix into the cavity part of this casting mold. Next, the pressure is applied on the fiber reinforced, polymerizable material and the fiber reinforced, polymerizable material is cured. The casting mold is so designed that the excess org. matrix leaks out of the cavity part during compression.
The four 50-minute TAU sessions were one-on-one individual therapy sessions. Therapy was mostly supportive therapy with an emphasis problem solving on increasing veteran motivation. A discussion of the antecedents to relapse would take place if a relapse occurred and coping skills were discussed and reviewed. Veterans were also connected with community-level psychosocial supports as appropriate.
BACKGROUND: Children with genetic conditions are at increased risk for mental health and neurodevelopmental problems, often accompanied by significant parental distress. Genetic and family factors can impact children and parents' mental health. Early parenting interventions, like the Incredible Years® programs, have demonstrated to improve parental distress and children's mental health. The recent version for young children with language delays or autism spectrum disorder (IY-ASLD®) has shown to be feasible and effective to support parents in their children's developmental trajectories. The effectiveness of treatments for children with genetic conditions and neurodevelopmental problems is largely unexplored, leaving significant gaps in evidence-based options. Clinicians lack guidance, especially when patients exhibit language or social communication impairments but do not meet diagnostic criteria for a full-blown autism spectrum disorder (ASD). We aim to fill this gap, providing evidence on the feasibility and effectiveness of the IY-ASLD® intervention for such patients.
METHODS: We designed a prospective multicenter pragmatic randomized controlled trial including approximately 68 children aged 3 to 7 years, recruited from three tertiary care reference hospitals. Inclusion criteria will necessitate genetic confirmation of a neurodevelopmental disorder along with language, communication, or socialization difficulties. Individuals with an ASD diagnosis will be excluded. All subjects are included in a territorial register for rare conditions (ReMin, Registre de Malalties Minoritàries de Catalunya). Families will randomly be assigned to the intervention or the control group. The intervention will be held online by clinical psychologists and child and adolescent psychiatrists.
DISCUSSION: Our group has recently piloted the online implementation of the IY-ASLD® intervention for the first time in Spain, for parents of children with language delays, socialization difficulties, or ASD, but not genetically determined. Our multicenter research consortium is well-positioned to recruit patients with rare conditions and implement efficient treatment pathways within the National Health System. Given the geographical dispersion of families affected by rare conditions, the online format offers logistical advantages and improved therapy access, enhancing homogeneity across all patients. The results of this study will inform clinicians and policymakers about evidence-based treatment options for this vulnerable and overlooked group of young children.
TRIAL REGISTRATION: ClinicalTrials.gov NCT06125093 . Date of registration: first submitted 2023-10-23; first posted 2023-11-09. URL of trial registry record.
The invention provides bacillus coagulans and application thereof, and belongs to the technical field of microorganisms. The Bacillus coagulans (Bacillus coagulans) HOM5301 disclosed by the invention is preserved in the China general microbiological culture Collection center of China Committee for culture Collection of microorganisms, the preservation number is CGMCC No.20383, and the preservation date is 2020, 7 and 16 days. The Bacillus coagulans strain can enhance organism immunity, enhance cellular immunity and monocyte-macrophage function, and inhibit proliferation of common pathogenic bacteria. Meanwhile, the bacillus coagulans strain can be fermented to produce fermented milk, oat milk, soybean milk and other fermented products. Has effects in enhancing immunity, promoting digestion, improving food nutrient availability, and improving taste. Has wide application prospect.
In accordance with the present invention, compositions comprising fluorine-containing magnetic resonance imaging agent(s) contained within polymeric shells are provided. Invention compositions are useful, for example, as contrast agents for magnetic resonance imaging (MRI). Fluorinated compounds in general are hydrophobic and as such have limited water solubility; thus the invention method permits preparation of such compounds in a biocompatible form suitable for ready delivery. The shell diameter is typically approximately 2 microns in diameter. Consequently, these materials have organ specificity due to rapid scavenging by the reticuloendothial system (RES) or the mononuclear phagocyte (MNP) system upon intravenous injection. Furthermore, fluorocarbon filled polymeric shells of the invention can be used to measure and monitor local oxygen and temperature.
Purpose: Although it is now understood that most antiglaucoma surgeries fail because of scarring of the filtering tract, the underlying mechanism remains to be elucidated. The present study investigated the mechanism by which the interleukin (IL)-22/IL-22 receptor alpha 1 (IL-22RA1) signaling pathway regulates scar formation in glaucoma patients. Method: A total of 31 glaucoma patients who underwent trabeculectomy surgery with uncontrollable intraocular pressure because of scarring and 19 strabismus patients as the control patient group were included in the present study. ELISA was performed to measure the content of IL-22 in peripheral blood. Serum from patients was used to incubate human Tenon's capsule fibroblasts (HTFs) cells and IL-22 antibody rescued the effect of IL-22 on the biological functions. qPCR and Western blot were performed to determine IL-22RA1 mRNA and protein expression levels. Flow cytometry was performed to assess the cell cycle distribution and the Cell Counting Kit-8 assay was used to analyze cell proliferation. Results: The ELISA assay revealed that the serum IL-22 level of glaucoma patients was significantly higher than the healthy group (29.80 ± 5.1 ng/µL vs. 5.21 ± 0.9 ng/µL). After incubation with patient serum, the proliferation and activation of human Tenon fibroblasts (HTFs) were promoted. IL-22 mediated the biological function of HTFs via directly binding IL-22RA1. Moreover, transfection of the siR-IL-22RA1 or IL-22RA1 gene resulted in significant antifibrosis or profibrosis in HTFs. When a signal transducer and activator of transcription (STAT) 3 inhibitor (BAY) was introduced to the IL-22RA1 overexpression group, IL-22-induced proliferation was reduced in HTFs. Additionally, glaucoma patients had increased levels of IL-22 expression following surgery. Conclusions: The IL-22/IL-22RA1/STAT3 signaling pathway promoted fibroblast cell proliferation and alpha-smooth muscle actin, potentially regulating fibrosis in glaucoma filtration tracts. Our results provide hitherto undocumented insights into the pathophysiology of postoperative scarring.
PURPOSE: To describe the incidence and management of delayed infections following frontalis sling suspension with polybutylate-coated polyester suture (Ethibond).
METHODS: Retrospective, interventional case series of 177 eyes of 150 patients, who underwent frontalis suspension surgery with Ethibond (Johnson and Johnson, USA), at L V Prasad Eye Institute, Hyderabad, India, between January 2016 and February 2022. Patients were assessed for chronic secondary sling infection, defined as infection/suture granuloma occurring beyond 6 weeks post-surgery. All patients received postoperative oral antibiotics. The clinical profile, microbiological evaluation, antibiotic sensitivity patterns, and management outcomes were analyzed.
RESULTS: Delayed infection following Ethibond sling suspension was noted in 14 eyes of 13 patients (7.9%). Of these, eight cases (61.5%) were females. The average time interval from surgery to presentation was 7.5 months (range: 2.5 months to 2.5 years). Eleven eyes underwent sling removal. Of the three who received initial antibiotic course, two eventually needed sling removal. Microbiological evaluation was available in seven eyes (50%), with Staphylococcus aureus as the most common organism. Of the six positive cultures, five (83.3%) were resistant to fluoroquinolones (FQs).
CONCLUSION: Frontalis suspension with Ethibond has an 8% incidence of delayed infections, with Staphylococcus aureus as the most common organism. The authors recommend early sling removal in all patients with infection and recommend consideration of an alternative material in the event of future revision surgery.
Polycystic Ovary Syndrome (PCOS) is a heterogeneous condition characterized by chronic anovulation and androgen excess that occurs in 4-8% of unselected adult women. Although signs and symptoms of the disorder typically appear at the time of puberty, diagnosis is often delayed until adulthood. At least 50% of adult women with PCOS are obese, resulting in a more severe clinical picture. Obesity among adolescents has been increasing in recent years, with overrepresentation of females who show evidence of hyperandrogenism and irregular periods, suggesting an association of obesity and PCOS at an early age. Recent data, however, have drawn attention to the long-term risks of PCOS, including diabetes and cardiovascular disease. Insulin resistance plays a critical role in the pathophysiology of PCOS and is thought to be the metabolic abnormality most closely linked to an increased risk of diabetes and heart disease. Traditional treatments with oral contraceptives are associated with reduction in serum androgens and improvements in menstrual cycles in adolescents with PCOS, however these have not been well-studied in obese adolescents. Oral contraceptives may worsen the dyslipidemia seen in obese women with PCOS and do not address the insulin resistance. Metformin, an insulin sensitizing agent, has been shown to improve metabolic features of PCOS, but combination therapy with oral contraceptives has never been studied in the obese adolescent with PCOS.

The major hypothesis of this proposal is that metformin will improve the metabolic profile of obese adolescent girls with PCOS treated with oral contraceptives. Additionally, a secondary hypothesis will be that compliance with a concurrent lifestyle modification program with be associated with the most significant improvements.
OBJECTIVE: Sarcopenia, as a condition of muscle mass loss and functional decline typically diagnosed in elderly individuals, severely affects human physical activity, metabolic homeostasis, and quality of life. Gui Qi Zhuang Jin Decoction (GQZJD), an approved hospital-based prescription with years of clinical application, has been demonstrated to have a notable therapeutic effect on sarcopenia. However, its potential mechanism of action in the treatment of sarcopenia remains uncertain.
METHODS: Ultra-performance liquid chromatography paired with Q Exactive™ HF-X mass spectrometry (UPLC-QE-MS) was used to identify the ingredients of GQZJD. Subsequently, GQZJD observed the basic growth and muscles of the sarcopenia mouse, while the behavioral indicators were also tested. Muscle histopathology and serum oxidative stress biochemicals were also detected, and mitochondrial function and energy metabolism-related indicators in the gastrocnemius muscle were examined. Then, a metabolomics strategy was applied to predict possible pathways involving mitochondria by which GQZJD could improve sarcopenia. Finally, quantitative real-time polymerase chain reaction and western blot analyses were carried out to validate the effects of GQZJD on sarcopenia-induced mitochondrial dysfunction, together with uncovering the associated mechanisms.
RESULTS: Twenty-seven ingredients absorbed into the blood (IAIBs) of GQZJD were identified using UPLC-QE-MS, which were regarded as the main active ingredients behind its sarcopenia treatment effects. GQZJD administration increased the body weight, gastrocnemius muscle mass, and autonomic activity, mitigated muscle tissue morphology and pathology; and alleviated the oxidative stress levels in sarcopenia mice. Treatment with GQZJD also decreased the mitochondrial reactive oxygen species level and serum lipid peroxide Malonaldehyde concentration. and increased the mitochondrial membrane potential, adenosine triphosphate level, 8‑hydroxy-2-deoxyguanosine content, mitochondrial DNA copy number, and the mitochondrial fission factor dynamin-related protein 1. Non-targeted metabolomics suggested that the sarcopenia therapeutic effect of GQZJD on sarcopenia may occur through the glycerophospholipid metabolism, choline metabolism in cancer, phenylalanine metabolism and tyrosine metabolism pathways, implying an association with AMP-activated protein kinase (AMPK) and related signals. Further, the molecular docking results hinted that AMPK performed well in terms of binding energy with the 27 IAIBs of GQZJD (average binding energy, -7.5 kcal/mol). Finally, we determined that GQZJD significantly activated the key targets of the AMPK/peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α)/nuclear factor erythroid 2-related factor 2 (Nrf2) axis..
CONCLUSIONS: Our results demonstrated that GQZJD ameliorated d-galactose-induced sarcopenia by promoting the animal behaviours, facilitating mitochondrial function and restoring mitochondrial energy metabolism. with its effects mediated by the AMPK/PGC-1α/Nrf2 axis. Over all, GQZJD represents a promising therapeutic candidate that ameliorated sarcopenia in aging mice.
Starting from the lateral third of the clavicle and moving distally and laterally to the midaxillary line. The pectoral major and minor muscles will be identified and 10 mL of bupivacaine 0.25% will be injected between the 2 muscles, and then move the ultrasound probe towards the axilla until the serratus anterior is identified above the second, third, and fourth ribs then injection of 20 mL of bupivacaine 0.25% after negative aspiration into the fascial plane between pectoralis minor and serratus anterior muscles.
PROBLEM TO BE SOLVED: To obtain the subject cosmetic capable of providing foam excellent in usability, safety and qualities, having a specific viscosity, comprising a fatty acid, an alkali, an anionic surfactant and a nonionic surfactant. SOLUTION: This cosmetic for shaving is obtained by formulating (A) 0.1-30wt.% of a fatty acid with (B) an alkali (e.g. triethanolamine) for neutralizing the component A, (C) 0.1-30wt.% of an anionic surfactant (e.g. coconut oil fatty acid sarcosine triethanolamine), (D) 0.01-10wt.% of a nonionic surfactant (e.g. coconut oil fatty acid diethanolamide) optionally and (E) an oil component, a humectant, an ultraviolet light absorber, a polymer, powder, vitamins, a medicine, perfume, etc., a nonionic surfactant and adjusting the mixture to <=100cps viscosity at 30 deg.C. When the cosmetic is housed in a foaming contained having one or plural porous membranes and used, it can be made into a foamy state without using a compressed liquefied gas, etc.
Participants assigned to the Body Positive condition (n=30) will be exposed to 15 different body positive images, with a manipulation checkpoint between every other image asking participants a basic question (such as what color was the swimsuit of the model in the previous image?) regarding characteristics of the last image they were exposed to.